Form 4: Catalyst Pharmaceuticals Executive Exercises Stock Options, Sells Shares to Cover Taxes

Preethi Sundaram, Chief Strategy Officer at Catalyst Pharmaceuticals, exercised stock options and sold shares to cover taxes on December 9, 2024.

Summary

• Preethi Sundaram, Chief Strategy Officer of Catalyst Pharmaceuticals, exercised 6,855 restricted stock units on December 9, 2024.
• These units converted into 6,855 shares of common stock.
• Sundaram then sold 2,415 shares to cover tax obligations related to the vesting of the restricted stock units.
• Following these transactions, Sundaram directly owns 29,981 shares of Catalyst Pharmaceuticals common stock.

Sentiment

Score: 5

Explanation: This is a routine transaction related to executive compensation and does not indicate any positive or negative sentiment about the company's performance.

Industry Context

This is a routine filing related to executive compensation and is common in publicly traded companies. It reflects the standard practice of granting stock-based compensation to executives and the subsequent tax obligations.

Comparison to Industry Standards

• Stock-based compensation is a common practice in the pharmaceutical industry to align executive interests with shareholder value.
• The vesting schedule of the restricted stock units, with tranches over three years, is typical for long-term incentive plans.
• The sale of shares to cover tax obligations is a standard procedure for executives exercising stock options or restricted stock units.

Stakeholder Impact

• The transaction has a minor impact on shareholders as it involves a small number of shares being sold by an executive.
• The transaction is part of the executive's compensation package and does not have a direct impact on employees, customers, or suppliers.

Key Dates

Keywords

Catalyst Pharmaceuticals, stock options, restricted stock units, insider trading, Form 4, executive compensation, Preethi Sundaram